Key result
Pfizer-BioNTech COVID-19 vaccine booster doses in adolescents aged 12-17 years resulted in primarily mild to moderate reactions, with 91.6% of VAERS reports classified as nonserious.
Why the study?
Is the Pfizer-BioNTech COVID-19 vaccine booster dose safe in adolescents aged 12-17 years?
Population
Adolescents aged 12-17 years receiving Pfizer-BioNTech booster doses in the United States
Comparison
Booster dose vs dose 2
Design
Surveillance study
Authors
Loading...
Reassures on mostly mild adolescent booster reactions; leaves open rare event confirmation via active surveillance.
Observational (n=3,418)
Is the Pfizer-BioNTech COVID-19 vaccine booster dose safe in adolescents aged 12-17 years?
The Pfizer-BioNTech COVID-19 vaccine booster dose in adolescents aged 12-17 years is associated primarily with mild to moderate expected reactions, with serious adverse events being rare.
Hause et al. (2022) conducted an observational in COVID-19 vaccination (n=3,418). Pfizer-BioNTech COVID-19 vaccine booster dose vs. dose 2 was evaluated on Adverse events reported to VAERS and v-safe. Pfizer-BioNTech COVID-19 vaccine booster doses in adolescents aged 12-17 years resulted in primarily mild to moderate reactions, with 91.6% of VAERS reports classified as nonserious.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: